Conor Set To Enroll Pivotal U.S. Study For CoStar Drug-Eluting Stent
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will begin enrollment of a 1,700-patient U.S. pivotal trial in coming weeks. Conor is touting the paclitaxel-eluting stent as unique because it incorporates hundreds of small holes that act as reservoirs, which can be loaded with a drug-polymer combination for more controlled release over time.